Credit: Amgen. The Repatha Pushtronix System will be discontinued as of June 30, 2024. Amgen has announced that the Repatha (evolocumab) Pushtronix ® System (single-dose on-body infusor with prefilled ...

Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...

ScPharmaceuticals has secured funding for commercialization of its recently approved on-body infusor, pricing a $50 million public offering ahead of the planned launch of the product early next year.

After five years and two unsuccessful attempts, scPharmaceuticals has finally pushed its on-body infusor for congestive heart failure across the FDA finish line. With the approval, Furoscix becomes ...

MannKind (MNKD) announced two business updates-approval of the FUROSCIX On-body Infusor for pediatric patients and issuance of additional intellectual property protection for the investigational-stage ...